GUELPH, ON, Oct. 26 /CNW/ - On September 13, 2007, ENPAR reported that a
major American water company ("COMPANY") had purchased DesEL units for field
testing the applicability of ENPAR's water treatment system for the North
American commercial and residential markets.
The purchase and ongoing evaluation program by that Company has been
postponed until at least the conclusion of the pending arbitration between
ENPAR and the licensor of an important component of the DesEL System. The
arbitration is scheduled to proceed on January 21, 2008 and anticipated to
last for 3 to 5 days. A decision by the Arbitrator is expected sometime after
the January hearing.
As previously reported, ENPAR believes that the arbitration will confirm
its compliance with the Non-exclusive Licensing Agreement, thereby providing
the basis for continuance of the agreement in good standing.
ENPAR continues to aggressively market its other 100% owned and
patented/patent pending, state-of-the-art electrochemical technologies for
metal recovery and water treatment.
ENPAR is a "Technology Company" applying its patented and proprietary
"Electrochemical Technologies" to the treatment of waste water and drinking
water contaminated by metals or nutrients i.e., nitrate/ammonia associated
with the mining, metal processing, chemical, agricultural, municipal and waste
management sectors. The common shares trade on Tier ll of the TSX Venture
Exchange under the symbol "ENP".
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements within the meaning
of the "safe harbour" provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are subject to risks and
uncertainties and other factors that may cause ENPAR Technologies Inc. results
to differ materially from expectations. These include risks relating to market
fluctuations, property performance and other risks. These forward-looking
statements speak only as of the date hereof.
For further information:
For further information: Dr. Gene Shelp, President and CEO, Tel: (519)
836-6155, Fax: (519) 836-5683, E-mail: firstname.lastname@example.org, Web Site: